Don B. Axworthy

778 citations

14 papers · 634 indexed · h-index 11

Co-authors: Oliver W. Press D. Scott Wilbur Don K. Hamlin Damon L. Meyer Hazel B. Breitz Paul L. Weiden Louis Theodore Robert W. Mallett
Topics: Radiopharmaceutical Chemistry and Applications (11 papers)Monoclonal and Polyclonal Antibodies Research (9 papers)Lymphoma Diagnosis and Treatment (7 papers)
Cited by: Radiology, Nuclear Medicine and Imaging Pathology and Forensic Medicine Oncology
Journals: Blood Analytical Biochemistry Bioconjugate Chemistry
Partner nations: United States Canada United Kingdom

In The Last Decade

Don B. Axworthy

14 papers receiving 622 citations

Peers

Countries citing papers authored by Don B. Axworthy

Since Specialization

Citations

This map shows the geographic impact of Don B. Axworthy's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Don B. Axworthy with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Don B. Axworthy more than expected).

Fields of papers citing papers by Don B. Axworthy

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Don B. Axworthy. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Don B. Axworthy. The network helps show where Don B. Axworthy may publish in the future.

Co-authorship network of co-authors of Don B. Axworthy

This figure shows the co-authorship network connecting the top 25 collaborators of Don B. Axworthy. A scholar is included among the top collaborators of Don B. Axworthy based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Don B. Axworthy. Don B. Axworthy is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

14 of 14 papers shown

#	Work	Indexed citations
1	Evaluation of Glycodendron and Synthetically Modified Dextran Clearing Agents for Multistep Targeting of Radioisotopes for Molecular Imaging and Radioimmunotherapy 2013 ·Molecular Pharmaceutics ·Sarah M. Cheal,Barney Yoo,Sarah Boughdad,Blesida Punzalan,Guangbin Yang,(unknown),(unknown),Jun Pu,Don B. Axworthy,Pat Zanzonico,Ouathek Ouerfelli,Steven M. Larson	9
2	Comparison of Pretargeted and Conventional CC49 Radioimmunotherapy Using ¹⁴⁹Pm, ¹⁶⁶Ho, and ¹⁷⁷Lu 2011 ·Bioconjugate Chemistry ·(unknown),Fang Jia,Jeffrey N. Bryan,(unknown),Cathy S. Cutler,Alan R. Ketring,William H. Miller,Jim Simón,R. Keith Frank,Louis Theodore,Don B. Axworthy,Silvia S. Jurisson,Michael R. Lewis	22
3	Comparative biodistributions of pretargeted radioimmunoconjugates targeting CD20, CD22, and DR molecules on human B-cell lymphomas 2007 ·Blood ·Anastasia Pantelias,John M. Pagel,(unknown),(unknown),(unknown),Donald K. Hamlin,D. Scott Wilbur,Yukang Lin,Diane Stone,Don B. Axworthy,Ajay K. Gopal,Oliver W. Press	29
4	Pretargeted Radioimmunotherapy (RIT) with a Novel Anti-TAG-72 Fusion Protein 2005 ·Cancer Biotherapy and Radiopharmaceuticals ·Andres Forero‐Torres,Sui Shen,Hazel B. Breitz,Robert B. Sims,Don B. Axworthy,M.B. Khazaeli,(unknown),Ivor Percent,(unknown),Albert F. LoBuglio	20
5	Pretargeted radioimmunotherapy in tumored mice using an in vivo 212Pb/212Bi generator 2005 ·Nuclear Medicine and Biology ·(unknown),Paul L. Beaumier,Don B. Axworthy,Robert W. Atcher,Alan R. Fritzberg	48
6	Phase 1 trial of a novel anti-CD20 fusion protein in pretargeted radioimmunotherapy for B-cell non-Hodgkin lymphoma 2004 ·Blood ·Andres Forero,Paul L. Weiden,Julie M. Vose,Susan J. Knox,Albert F. LoBuglio,Jordan Hankins,Michael L. Goris,Vincent J. Picozzi,Don B. Axworthy,Hazel B. Breitz,Robert B. Sims,Richard Ghalie,Sui Shen,Ruby F. Meredith	117
7	Role of Biotin-Binding Affinity in Streptavidin-Based Pretargeted Radioimmunotherapy of Lymphoma 2004 ·Bioconjugate Chemistry ·Kevin J. Hamblett,Oliver W. Press,Damon L. Meyer,Don K. Hamlin,Don B. Axworthy,D. Scott Wilbur,Patrick S. Stayton	27
8	Combination therapy with Pretarget CC49 radioimmunotherapy and gemcitabine prolongs tumor doubling time in a murine xenograft model of colon cancer more effectively than either monotherapy. 2003 ·PubMed ·Scott S. Graves,(unknown),Yukang Lin,(unknown),James Sanderson,Jody Schultz,(unknown),David F. Gray,Don B. Axworthy,Heather M. Jones,(unknown)	44
9	Comparison of immunoscintigraphy, efficacy, and toxicity of conventional and pretargeted radioimmunotherapy in CD20-expressing human lymphoma xenografts. 2003 ·PubMed ·(unknown),Don K. Hamlin,John M. Pagel,D. Scott Wilbur,Damon L. Meyer,Don B. Axworthy,Robert W. Mallett,Louis Theodore,Patrick S. Stayton,Oliver W. Press	57
10	Preparation of ²¹³bi‐dota‐biotin in high specific activity for pretargeted alpha radiotherapy of cancer 2001 ·Journal of Labelled Compounds and Radiopharmaceuticals ·Mark D. Hylarides,Don B. Axworthy,Alan R. Fritzberg	1
11	A comparative evaluation of conventional and pretargeted radioimmunotherapy of CD20-expressing lymphoma xenografts 2001 ·Blood ·Oliver W. Press,(unknown),(unknown),Don K. Hamlin,D. Scott Wilbur,Timothy A. Johnson,Louis Theodore,Eric Kin Cheong Yau,Robert W. Mallett,Damon L. Meyer,Don B. Axworthy	121
12	Pretargeted Radioimmunotherapy (PRIT™) for Treatment of Non-Hodgkin's Lymphoma (NHL): Initial Phase I/II Study Results 2000 ·Cancer Biotherapy and Radiopharmaceuticals ·Paul L. Weiden,Hazel B. Breitz,Oliver W. Press,(unknown),(unknown),(unknown),Diane Stone,Don B. Axworthy,Darrell R. Fisher,John M. Reno	110
13	Quantitative Analysis of a Synthetic Peptide, NR58-3.14.3, in Serum by LC-MS with Inclusion of a Diastereomer as Internal Standard 2000 ·Analytical Biochemistry ·Sibylle Wilbert,(unknown),Eric Kin Cheong Yau,David J. Grainger,(unknown),Don B. Axworthy	21
14	Molecular modeling and preclinical evaluation of the humanized NR-LU-13 antibody. 1999 ·PubMed ·Scott S. Graves,(unknown),Diane Stone,Don B. Axworthy,John M. Reno,(unknown),Stephen M. J. Searle,Andrew Henry,Jan T. Pedersen,Anthony R. Rees,Randell T. Libby	8

About Don B. Axworthy

Don B. Axworthy is a scholar working on Radiology, Nuclear Medicine and Imaging, Pathology and Forensic Medicine and Cell Biology, having authored 14 papers that have together received 634 indexed citations. Recurring topics across this work include Radiopharmaceutical Chemistry and Applications (11 papers), Monoclonal and Polyclonal Antibodies Research (9 papers) and Lymphoma Diagnosis and Treatment (7 papers). The work is most often cited by research in Radiology, Nuclear Medicine and Imaging (524 citations), Pathology and Forensic Medicine (204 citations) and Oncology (134 citations). Don B. Axworthy has collaborated with scholars based in United States, Canada and United Kingdom. Frequent co-authors include Oliver W. Press, D. Scott Wilbur, Don K. Hamlin, Damon L. Meyer, Hazel B. Breitz, Paul L. Weiden, Louis Theodore, Robert W. Mallett, Eric Kin Cheong Yau and Diane Stone. Their work appears in journals such as Blood, Analytical Biochemistry and Bioconjugate Chemistry.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact